称“好戏还在后头,公司已回归基本面”的辉瑞CEO,正面临着公司历经数次挫折后遭到股东和投资者的极大质疑的境况。而神秘投资者的强势入股,能让辉瑞重回巅峰吗?撰文| 序诗继54亿美元并购而来的镰刀型细胞病(SCD)药物Oxbryta从全球市场撤回,5.25亿美元引进的口服RSV疗法打水漂后,有些“水逆”的辉瑞迎来潜在转折性一刻:华尔街知名的激进投资者/维权投资基金Starboard Value以10...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.